Pharma marketers enter 2026 asking where DTC fits in the DTP era.  | Pharma marketers enter 2026 asking where DTC fits in the ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

“Healthcare and pharma are steadily moving past a TV-first mindset. While linear TV made up more than 30% of the industry’s ...

As 2025 closes, biopharma and healthcare are learning to live on shifting ground. | Fierce reporters break down the forces that shaped biopharma and healthcare in 2025 and what lies ahead in 2026.

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | ...

The deal with the U.K.’s Nuclear Decommissioning Authority runs for 15 years with an option to renew for a “potentially ...

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...